| 发明名称 |
Biochemical Markers for CVD Risk Assessment |
| 摘要 |
A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage ofmimecan, a protein of an atherosclerotic plaque, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events. |
| 申请公布号 |
US2015118698(A1) |
申请公布日期 |
2015.04.30 |
| 申请号 |
US201214116924 |
申请日期 |
2012.05.04 |
| 申请人 |
Nordic Biosciences A/S |
发明人 |
Michaelsen Natas[c]ha Barascuk;Genovese Federica;Karsdal Morten;Leeming Diana Julie |
| 分类号 |
G01N33/68;C07K14/47;C07K16/18 |
主分类号 |
G01N33/68 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage in vivo of mimecan by a proteinase, said method comprising contacting a sample comprising said peptide fragments with an immunological binding partner having specific binding affinity for a said neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. |
| 地址 |
Herlev DK |
